In the STAM NASH model, streptozotocin (STZ) is administered to produce inflammation, impairment of insulin secretion, and elucidate the resultant phenotype for advanced type 2 diabetes (T2D) [18]. Here, INS is linked to type 2 diabetes mellitus.